aBLA Filing Intelligence & Biosimilar Opportunity

Veopoz

Pozelimab-Bbfg

Immunomodulators

IV Infusion

Veopoz is an antibody injection that treats CHAPLE disease, a rare genetic disorder causing protein loss and chronic intestinal inflammation. It works by blocking complement C5, helping to stabilize protein levels and reduce hospital visits in both children and adults.

Approval Date

18-Aug-23

Data Exclusivity Expiry

18-Aug-27

Market Exclusivity Expiry

18-Aug-35

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

153

2029

232

2030

292

2031

332

2032

359

Molecule profile

Details & specifications

Molecule

Pozelimab-Bbfg

Innovator

REGENERON PHARMACEUTICALS, INC.

Dosage Form

IV Infusion

Strength

400 mg/2 mL

Therapeutic Category

Immunomodulators

Usage

To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets